FDA says Covid vaccines will probably get an annual update but most people will likely need only one shot

FDA says Covid vaccines will probably get an annual update but most people will likely need only one shot


Justin Sullivan | Getty Images

The Food and Drug Administration has laid out a road map for what Covid-19 vaccination may look like moving forward.

In a briefing document published Monday, the FDA said the vaccines will probably need an annual update as the virus continues to evolve. The agency would select the Covid strain for the vaccine in the spring so the updated shots could roll out every September in time for a fall vaccination campaign.

Most people would receive one shot to restore their protection against the virus moving forward, according to the briefing document. This would apply to people who have been exposed to the virus’s spike protein at least twice, either through vaccination or infection.

But older adults and people with compromised immune systems may need two doses, according to the proposed vaccination schedule. Young children who have received only one shot previously would also get two doses.

The FDA released the road map ahead of a meeting of the agency’s independent vaccine experts scheduled for Thursday. The expert panel will vote on whether to make all Covid vaccines in the U.S. bivalent shots, meaning they protect against both the omicron BA.5 subvariant as well as the original strain of Covid discovered in Wuhan, China, in late 2019.

Currently, only Moderna’s and Pfizer’s booster doses target the omicron variant. If adopted, the primary series would also contain the omicron strain.

The proposed system for updating Covid vaccines resembles how the FDA selects flu shots every year. The agency said it could update and rollout the Covid vaccines without clinical data, which is also the case with the annual process to change the flu shot.

The Centers for Disease Control and Prevention on Thursday is also expected to provide more information about an investigation into what it has described as a “very unlikely” risk of stroke in seniors who received Pfizer’s omicron booster.

The CDC received preliminary safety concern data from its Vaccine Safety Datalink late last year. A subsequent review for four other major databases did not identify an increased risk for stroke, but the CDC investigation is ongoing.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More